Ultima Genomics' UG 100™ Selected for Landmark UK Biobank Proteome Study
Ultima Genomics has recently announced a significant milestone in medical research by having its UG 100™ sequencing platform selected for the UK Biobank's ambitious proteomics study. This project highlights the potential and efficiency of Ultima's ultra-high throughput next-generation sequencing (NGS) technology, aiming to provide pivotal insights into the relationship between protein levels and disease progression. The initiative is backed by a group of 14 leading biopharmaceutical companies and will be the largest and most comprehensive protein study ever conducted.
The aim of the UK Biobank study is to explore how changes in protein levels during different stages of life can influence overall health and the progression of diseases. Over the course of this vast research effort, more than 5,400 protein markers will be quantified across an extensive dataset comprising 600,000 samples, which includes contributions from half a million UK Biobank participants. Notably, the study also involves collecting 100,000 follow-up samples over various time points, allowing researchers to track and analyze how protein expressions vary over an extended period, sometimes spanning up to 15 years.
According to Ultima Genomics CEO Gilad Almogy, this selection is a testament to the impressive scaling and cost-effectiveness of their sequencing technology, facilitating extensive research collaborations while combating the challenges typically associated with larger studies. The UG 100™ platform will work in tandem with Thermo Fisher Scientific's Olink® Explore HT proteomics technology, forming a powerful alliance aimed at enriching our understanding of human genomics and aiding the transition into a new era of health analysis.
This groundbreaking collaboration emphasizes the importance of proteomics as a critical tool in drug discovery, shedding light on how molecular drivers contribute to disease mechanisms and various health outcomes. Dr. Chris Whelan, the Pharma Proteomics Project Lead, expressed excitement about the potential of this dataset to transform biomarker identification and improve disease prediction methods, reinforcing the relevance of proteomics in modern medicine.
With technology like the UG 100™, which aims to lower the barriers associated with genomic information access, researchers now have the opportunity to conduct more extensive and thorough investigations at a population scale. The platform's capacity makes it an ideal candidate to support initiatives aspiring to add diverse layers of genomic data, such as the integration of proteomics alongside traditional nucleic acid sequencing.
As expressed by Carl Raimond, President of Proteomic Sciences at Thermo Fisher Scientific, this project could indeed reshape our understanding of disease and patient care. He emphasizes that the collaborative synergy between both companies enhances the potential for groundbreaking advancements in healthcare solutions, setting the stage for novel therapeutic approaches that rely on comprehensive biological insights.
The sequencing operations for the UK Biobank project will take place at the Regeneron Genetics Center, which is recognized as a leading facility in human genetic research. This partnership with Regeneron further cements UG 100's capabilities in meeting the high demands for large-scale genomic data production, showcasing its critical role in fuelling the next phase of proteomic research.
Ultima Genomics is committed to their mission of revolutionizing genomics by providing scalable solutions that address biology's intricacies. As this study unfolds, the data generated is expected to illuminate new pathways and correlations that will ultimately drive advancements in personalized medicine, enhancing our capacity to understand and potentially predict health outcomes based on protein dynamics. Such efforts signify a forward leap in medical research, pushing the boundaries of what is possible within genomic and proteomic fields. As scientists and researchers look forward to what this collaboration will yield, the implications for future studies and medical advancements are vast, promising a transformative impact on healthcare globally.
The aim of the UK Biobank study is to explore how changes in protein levels during different stages of life can influence overall health and the progression of diseases. Over the course of this vast research effort, more than 5,400 protein markers will be quantified across an extensive dataset comprising 600,000 samples, which includes contributions from half a million UK Biobank participants. Notably, the study also involves collecting 100,000 follow-up samples over various time points, allowing researchers to track and analyze how protein expressions vary over an extended period, sometimes spanning up to 15 years.
According to Ultima Genomics CEO Gilad Almogy, this selection is a testament to the impressive scaling and cost-effectiveness of their sequencing technology, facilitating extensive research collaborations while combating the challenges typically associated with larger studies. The UG 100™ platform will work in tandem with Thermo Fisher Scientific's Olink® Explore HT proteomics technology, forming a powerful alliance aimed at enriching our understanding of human genomics and aiding the transition into a new era of health analysis.
This groundbreaking collaboration emphasizes the importance of proteomics as a critical tool in drug discovery, shedding light on how molecular drivers contribute to disease mechanisms and various health outcomes. Dr. Chris Whelan, the Pharma Proteomics Project Lead, expressed excitement about the potential of this dataset to transform biomarker identification and improve disease prediction methods, reinforcing the relevance of proteomics in modern medicine.
With technology like the UG 100™, which aims to lower the barriers associated with genomic information access, researchers now have the opportunity to conduct more extensive and thorough investigations at a population scale. The platform's capacity makes it an ideal candidate to support initiatives aspiring to add diverse layers of genomic data, such as the integration of proteomics alongside traditional nucleic acid sequencing.
As expressed by Carl Raimond, President of Proteomic Sciences at Thermo Fisher Scientific, this project could indeed reshape our understanding of disease and patient care. He emphasizes that the collaborative synergy between both companies enhances the potential for groundbreaking advancements in healthcare solutions, setting the stage for novel therapeutic approaches that rely on comprehensive biological insights.
The sequencing operations for the UK Biobank project will take place at the Regeneron Genetics Center, which is recognized as a leading facility in human genetic research. This partnership with Regeneron further cements UG 100's capabilities in meeting the high demands for large-scale genomic data production, showcasing its critical role in fuelling the next phase of proteomic research.
Ultima Genomics is committed to their mission of revolutionizing genomics by providing scalable solutions that address biology's intricacies. As this study unfolds, the data generated is expected to illuminate new pathways and correlations that will ultimately drive advancements in personalized medicine, enhancing our capacity to understand and potentially predict health outcomes based on protein dynamics. Such efforts signify a forward leap in medical research, pushing the boundaries of what is possible within genomic and proteomic fields. As scientists and researchers look forward to what this collaboration will yield, the implications for future studies and medical advancements are vast, promising a transformative impact on healthcare globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.